HilleVax, Inc. (HLVX) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative vaccines, with a primary focus on tackling the significant global burden of norovirus-related illnesses. The company’s journey has been marked by both progress and challenges, as it navigates the complex and competitive landscape of the vaccine industry.
Company Background
Founded in March 2020 under the name MokshaCo, Inc., the company underwent a significant transformation in February 2021 when it changed its name to HilleVax and merged with North Bridge V, Inc. and YamadaCo III, Inc., with HilleVax emerging as the surviving entity. The company was initially formed with the purpose of identifying potential assets around which to build an operating company. Since its inception, HilleVax has dedicated substantially all of its efforts to organizing and staffing the company, business planning, raising capital, in-licensing its initial vaccine candidate, HIL-214, preparing for and managing clinical trials, and providing general and administrative support for these operations.
Business Overview
As a relatively young company with a limited operating history, HilleVax has yet to generate any revenue, and the sales and income potential of its business remains unproven. To fund its operations, the company has relied on various financing methods, including the issuance of convertible promissory notes, commercial bank debt, and the sale of common stock. Notably, HilleVax completed its initial public offering in May 2022 and conducted an underwritten public offering in September 2023, both of which provided crucial capital for its ongoing operations and research efforts.
HilleVax operates primarily in the United States and is focused on developing and commercializing novel vaccines. Its lead program has been HIL-214, a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Product Development
HilleVax’s journey began with the in-licensing of the HIL-214 technology from Takeda Vaccines, Inc. in 2021. This strategic move provided the company with a promising vaccine candidate that had previously been studied in nine clinical trials, generating safety data from more than 4,500 subjects and immunogenicity data from over 2,200 individuals, including more than 800 pediatric subjects.
Buoyed by the encouraging data from these earlier studies, HilleVax initiated a Phase 2b clinical trial, known as NEST-IN1, in May 2022 to evaluate the safety, immunogenicity, and efficacy of HIL-214 in infants. The study enrolled 2,800 infants and was designed to build upon the promising results observed in previous trials.
Clinical Trial Results
However, in July 2024, HilleVax announced that the NEST-IN1 study had failed to meet its primary or secondary efficacy endpoints. The vaccine demonstrated a mere 5% efficacy against moderate or severe norovirus-related AGE, falling short of the company’s expectations. This setback prompted HilleVax to discontinue further development of HIL-214 in the infant population.
Strategic Pivot
Despite the disappointing results of the NEST-IN1 study, HilleVax remains committed to exploring the potential for continued development of its norovirus vaccine candidates, including HIL-214 and its more recently acquired candidate, HIL-216, in the adult population. The company believes that the adult market may present a more promising opportunity, given the significant unmet need and the potential for improved vaccine performance in this age group.
Operational Restructuring
To navigate the challenges presented by the NEST-IN1 trial failure, HilleVax has taken decisive action to preserve its financial resources and maintain core capabilities. In July 2024, the company announced a workforce reduction of approximately 41 employees, or 40% of its total workforce. This move is intended to reduce operating expenses while allowing the company to focus on its ongoing R&D efforts and business development activities related to its norovirus vaccine candidates.
Furthermore, in October 2024, HilleVax announced an additional workforce reduction of approximately 15 employees, or 25% of its remaining workforce. The company estimates that it will incur charges of approximately $1.3 million primarily related to employee severance payments, benefits, and related termination costs associated with this workforce reduction. These actions are aimed at preserving cash while maintaining core capabilities as the company explores strategic options.
Financials
As of September 30, 2024, HilleVax reported $189.3 million in cash, cash equivalents, and marketable securities, providing the company with a solid financial foundation to continue its operations and explore strategic alternatives for its norovirus vaccine pipeline.
For the fiscal year 2023, HilleVax reported no revenue, a net loss of $123,566,000, operating cash flow (OCF) of -$86,783,000, and free cash flow (FCF) of -$97,531,000. In the most recent quarter (Q3 2024), the company again reported no revenue, with a net loss of $25,823,000, OCF of -$27,822,000, and FCF of -$14,209,000.
The company’s net loss and cash burn increased year-over-year due to higher research and development expenses related to the clinical development of its norovirus vaccine candidate HIL-214, as well as impairment charges on its long-lived assets. For the nine months ended September 30, 2024, HilleVax reported a net loss of $113.3 million, compared to a net loss of $86.6 million for the same period in 2023.
Research and development expenses were $72.7 million and $73.4 million for the nine months ended September 30, 2024 and 2023, respectively. The company also incurred $15.3 million in in-process research and development expenses related to the licensing agreement for its norovirus vaccine candidate HIL-216 in 2024. Additionally, HilleVax recorded $8.2 million in impairment charges on its long-lived assets during the nine months ended September 30, 2024, primarily due to the decline in the company’s market capitalization following the top-line data readout from the NEST-IN1 trial.
Liquidity
HilleVax’s liquidity position remains strong, with a debt-to-equity ratio of 0 as the company had no long-term debt as of September 30, 2024. The current ratio and quick ratio both stood at 14.25 as of the same date, indicating robust short-term liquidity.
The company had previously secured a $75 million term loan facility with Hercules Capital, of which $25.24 million was outstanding as of September 30, 2024. However, HilleVax repaid the entire outstanding balance in July 2024, further strengthening its balance sheet.
The company’s focus in the near-term will be on evaluating the potential for further development of HIL-214 and HIL-216 in adults, as well as pursuing business development opportunities that may unlock additional value for its shareholders.
Conclusion
HilleVax’s journey has been marked by both progress and setbacks, but the company remains committed to addressing the significant global burden of norovirus-related illnesses. With a revised strategy and a focus on the adult population, HilleVax is determined to navigate the evolving norovirus vaccine landscape and deliver innovative solutions that can positively impact public health.
The company’s financial performance in the first nine months of 2024 was characterized by continued research and development investments in its norovirus vaccine pipeline, the acquisition of rights to a new norovirus vaccine candidate, and the impact of the discontinuation of the HIL-214 program. These factors led to impairment charges and workforce reductions as the company evaluates its strategic options going forward.
Despite these challenges, HilleVax’s strong liquidity position and streamlined operations provide a foundation for exploring new opportunities in the adult norovirus vaccine market and pursuing potential strategic alternatives. As the company moves forward, it will need to carefully manage its resources while seeking to capitalize on its existing vaccine candidates and scientific expertise in the field of infectious diseases.
Disclaimer: This article is for informational purposes only. It does not constitute financial, legal, or other types of advice. While every effort has been made to ensure the accuracy of the information presented here, the author and the publisher do not make any guarantees about the completeness, reliability, and accuracy of this information.